Prevalence of antibody to Bordetella pertussis antigens in serum specimens obtained from 1793 adolescents and adults
- PMID: 15578376
- DOI: 10.1086/425003
Prevalence of antibody to Bordetella pertussis antigens in serum specimens obtained from 1793 adolescents and adults
Abstract
Serum specimens were obtained from all subjects in the adolescent and adult acellular pertussis (aP) vaccine efficacy trial before and after immunization to study the prevalence of IgG and IgA antibody and geometric mean titers to 4 Bordetella pertussis antigens. Of 1793 adolescents and adult subjects who received aP vaccine, only 20%, 68%, 59%, and 39% had concentrations of IgG antibodies to pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3, respectively, that were greater than or equal to the limit of quantitation of the enzyme-linked immunosorbent assay used in the analysis. There was minimal variation in antibody prevalence with respect to geographic area, age, sex, or race.
Comment in
-
The 100-day cough: the time for prevention has arrived.Clin Infect Dis. 2004 Dec 1;39(11):1581-2. doi: 10.1086/425012. Epub 2004 Nov 10. Clin Infect Dis. 2004. PMID: 15578354 No abstract available.
Similar articles
-
Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study.J Infect Dis. 2004 Aug 1;190(3):535-44. doi: 10.1086/422035. Epub 2004 Jul 7. J Infect Dis. 2004. PMID: 15243929 Clinical Trial.
-
Seroprevalence of IgG antibodies against Bordetella pertussis in healthy individuals aged 4-24 years in Turkey.Clin Microbiol Infect. 2008 Apr;14(4):388-90. doi: 10.1111/j.1469-0691.2007.01926.x. Epub 2008 Jan 7. Clin Microbiol Infect. 2008. PMID: 18190581
-
Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population.Vaccine. 2006 Mar 15;24(12):2043-8. doi: 10.1016/j.vaccine.2005.11.024. Epub 2005 Nov 28. Vaccine. 2006. PMID: 16356597
-
[Laboratory diagnosis of pertussis. Role of serology].Enferm Infecc Microbiol Clin. 2002 May;20(5):212-8. Enferm Infecc Microbiol Clin. 2002. PMID: 12006259 Review. Spanish.
-
Bordetella pertussis strain variation and evolution postvaccination.Expert Rev Vaccines. 2009 Jul;8(7):863-75. doi: 10.1586/erv.09.46. Expert Rev Vaccines. 2009. PMID: 19538113 Review.
Cited by
-
A new socioeconomic status measure for vaccine research in children using individual housing data: a population-based case-control study.BMC Public Health. 2016 Sep 21;16(1):1000. doi: 10.1186/s12889-016-3673-x. BMC Public Health. 2016. PMID: 27655468 Free PMC article.
-
Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin.PLoS One. 2010 Dec 28;5(12):e14442. doi: 10.1371/journal.pone.0014442. PLoS One. 2010. PMID: 21203437 Free PMC article. Clinical Trial.
-
Cellular immunity in adolescents and adults following acellular pertussis vaccine administration.Clin Vaccine Immunol. 2007 Mar;14(3):288-92. doi: 10.1128/CVI.00364-06. Epub 2007 Jan 31. Clin Vaccine Immunol. 2007. PMID: 17267589 Free PMC article.
-
Evaluation of a tetraplex microsphere assay for Bordetella pertussis antibodies.Clin Vaccine Immunol. 2006 Feb;13(2):266-70. doi: 10.1128/CVI.13.2.266-270.2006. Clin Vaccine Immunol. 2006. PMID: 16467336 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
